Company news

Savara, Inc. news in 2025

Savara, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

December 21, 2025

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

December 16, 2025

Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

December 10, 2025

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

December 1, 2025

Savara Announces Participation in Upcoming Investor Healthcare Conferences

November 19, 2025

Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

November 11, 2025

Savara Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M

October 30, 2025

Savara Announces Proposed Public Offering

October 28, 2025

Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants

October 28, 2025

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

October 28, 2025

Savara Announces Chief Medical Officer (CMO) Transition

October 16, 2025

Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025

October 1, 2025

Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025

September 28, 2025

Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis

September 1, 2025

New England Journal of Medicine (NEJM) to Publish Results From Savara’s Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

August 19, 2025

Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025

August 17, 2025

Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update

August 12, 2025

Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)

May 26, 2025

Savara Announces Participation in Jefferies Global Healthcare Conference

May 21, 2025

Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025

May 17, 2025

Savara Reports First Quarter 2025 Financial Results and Provides a Business Update

May 12, 2025

Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference

May 11, 2025

Savara Announces Participation in the Upcoming Citizens Life Sciences Conference

May 1, 2025

Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences

April 6, 2025

Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

March 26, 2025

Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital

March 25, 2025

Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

March 25, 2025

Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025

March 16, 2025

Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

March 5, 2025

Savara Announces Participation in the Leerink Global Healthcare Conference

March 2, 2025

Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research

January 29, 2025

Savara Announces Participation in Upcoming Healthcare Investor Conferences

January 28, 2025

Decks in 2025